Financière de Tubize S.A.
TUB
Rang în acțiuni
#2220
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Preț acțiune
$203.04
Capitalizare de piață
$9.04B
Schimbare (1 zi)
-7.47%
Schimbare (1 an)
-25.36%
Țară
BE
Tranzacționează Financière de Tubize S.A. (TUB)
Categorie
Healthcare
Raport P/B pentru Financière de Tubize S.A. (TUB)
Raport P/B la data de October 2026 TTM: 3.88
Conform celor mai recente rapoarte financiare și prețului acțiunilor Financière de Tubize S.A., raportul P/B actual (TTM) este 3.88. La sfârșitul anului 2023, compania avea un P/B de 1.78.
Istoricul raportului P/B pentru Financière de Tubize S.A. din 2003 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 3.88 | 12.83% |
| 2024 | 3.44 | 93.61% |
| 2023 | 1.78 | -1.27% |
| 2022 | 1.80 | 45.33% |
| 2021 | 1.24 | -5.96% |
| 2020 | 1.32 | 23.95% |
| 2019 | 1.06 | -8.04% |
| 2018 | 1.15 | -16.50% |
| 2017 | 1.38 | 2.53% |
| 2016 | 1.35 | -13.33% |
| 2015 | 1.56 | 7.29% |
| 2014 | 1.45 | 7.13% |
| 2013 | 1.35 | 40.45% |
| 2012 | 0.96 | 37.78% |
| 2011 | 0.70 | 3.15% |
| 2010 | 0.68 | -15.07% |
| 2009 | 0.80 | 63.65% |
| 2008 | 0.49 | -56.17% |
| 2007 | 1.11 | -37.19% |
| 2006 | 1.77 | -9.56% |
| 2005 | 1.96 | -22.63% |
| 2004 | 2.53 | -19.22% |
| 2003 | 3.14 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | 61.05% |
US
|
|
| 13.2547 | 241.50% |
US
|
|
| 4.208 | 8.42% |
AU
|
|
| 6.1824 | 59.29% |
NL
|
|
| - | - |
CH
|
